Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]

Yardley DA. Breast Cancer Targets Therapy. 2015:7;293–301.On page 300, Disclosure section, “The author reports no conflicts of interest in the work” has been updated since publication and should read “Dr Yardley reports nonfinancial support from Celgene pertai...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Yardley DA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b58e87eb8d3547e6b2991eacd2d9bdeb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b58e87eb8d3547e6b2991eacd2d9bdeb
record_format	dspace
spelling	oai:doaj.org-article:b58e87eb8d3547e6b2991eacd2d9bdeb2021-12-02T01:28:26ZTaxanes in the elderly patient with metastatic breast cancer [Corrigendum]1179-1314https://doaj.org/article/b58e87eb8d3547e6b2991eacd2d9bdeb2019-05-01T00:00:00Zhttps://www.dovepress.com/taxanes-in-the-elderly-patient-with-metastatic-breast-cancer-corrigend-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Yardley DA. Breast Cancer Targets Therapy. 2015:7;293–301.On page 300, Disclosure section, “The author reports no conflicts of interest in the work” has been updated since publication and should read “Dr Yardley reports nonfinancial support from Celgene pertaining to the work submitted. Dr Yardley reports grants to her institution, Sarah Cannon Research Institute, for studies on which she served as Principal Investigator, outside of the submitted work, from the following companies: Novartis, Janssen, Roche/Genentech, Bristol-Myers Squibb, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Medimmune, Medivation, Pfizer, Sanofi, Tesaro, Eisai, AbbVie, Astellas, Biomarin, Celldex, Clovis, Incyte, Merrimack, Imclone, Luitpold, Macrogenics, and Veridex. Dr Yardley reports that consulting fees were paid to her institution by the following companies for Dr Yardley’s services: Novartis, Roche/Genentech, Celgene, Lilly, Pfizer, Abraxis, Eisai, Spectrum, bioTheranostics, Celldex and OncoPlex Diagnostics. Dr Yardley reports non-financial support to her institution from Astellas, Sanofi, Lilly, and Celgene. The author reports no other conflicts of interest in this work”.Read the original article.Yardley DADove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 11, Pp 189-190 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yardley DA Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
description	Yardley DA. Breast Cancer Targets Therapy. 2015:7;293–301.On page 300, Disclosure section, “The author reports no conflicts of interest in the work” has been updated since publication and should read “Dr Yardley reports nonfinancial support from Celgene pertaining to the work submitted. Dr Yardley reports grants to her institution, Sarah Cannon Research Institute, for studies on which she served as Principal Investigator, outside of the submitted work, from the following companies: Novartis, Janssen, Roche/Genentech, Bristol-Myers Squibb, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Medimmune, Medivation, Pfizer, Sanofi, Tesaro, Eisai, AbbVie, Astellas, Biomarin, Celldex, Clovis, Incyte, Merrimack, Imclone, Luitpold, Macrogenics, and Veridex. Dr Yardley reports that consulting fees were paid to her institution by the following companies for Dr Yardley’s services: Novartis, Roche/Genentech, Celgene, Lilly, Pfizer, Abraxis, Eisai, Spectrum, bioTheranostics, Celldex and OncoPlex Diagnostics. Dr Yardley reports non-financial support to her institution from Astellas, Sanofi, Lilly, and Celgene. The author reports no other conflicts of interest in this work”.Read the original article.
format	article
author	Yardley DA
author_facet	Yardley DA
author_sort	Yardley DA
title	Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
title_short	Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
title_full	Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
title_fullStr	Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
title_full_unstemmed	Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
title_sort	taxanes in the elderly patient with metastatic breast cancer [corrigendum]
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/b58e87eb8d3547e6b2991eacd2d9bdeb
work_keys_str_mv	AT yardleyda taxanesintheelderlypatientwithmetastaticbreastcancercorrigendum
_version_	1718403096742199296

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]

Ejemplares similares